Gregory B. Kenny
Known title: DirectorCIK: 0001179497
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cardinal Health Hits Record Highs as Sector Strength Continues. Cardinal Health's stock has reached record highs, outperforming the broader market as the healthcare sector shows strong momentum. In corporate news, Senior Vice President Shane Abeyratne has joined the Customer Experience Advisory Board of Level AI. Meanwhile, market observers are looking ahead to the company's upcoming Q1 2027 earnings report and its position as a defensive option in the current economic environment.
Transaction History
| INGR | ▲ Buy | Grant | 346 | $39K | 3/31/2026 | View on chart |
| INGR | ▲ Buy | Grant | 371 | $40K | 12/5/2025 | View on chart |
| CAH | ▲ Buy | Grant | 1,702 | $0 | 11/5/2025 | View on chart |
| INGR | ▲ Buy | Grant | 321 | $40K | 9/30/2025 | View on chart |
| INGR | ▲ Buy | Grant | 291 | $40K | 6/30/2025 | View on chart |
| INGR | ▲ Buy | Grant | 302 | $40K | 3/31/2025 | View on chart |
| INGR | ▲ Buy | Grant | 275 | $40K | 12/12/2024 | View on chart |
| CAH | ▲ Buy | Grant | 2,812 | $0 | 11/6/2024 | View on chart |
| INGR | ▲ Buy | Grant | 295 | $40K | 9/30/2024 | View on chart |
| INGR | ▲ Buy | Grant | 347 | $40K | 6/28/2024 | View on chart |
| INGR | ▲ Buy | Grant | 342 | $40K | 3/29/2024 | View on chart |
| INGR | ▲ Buy | Grant | 361 | $38K | 12/11/2023 | View on chart |
| CAH | ▲ Buy | Grant | 3,193 | $0 | 11/15/2023 | View on chart |
| INGR | ▲ Buy | Grant | 377 | $37K | 9/29/2023 | View on chart |
| INGR | ▲ Buy | Grant | 354 | $38K | 6/30/2023 | View on chart |
| INGR | ▲ Buy | Grant | 381 | $37K | 3/31/2023 | View on chart |
| CAH | ▲ Buy | Grant | 3,867 | $0 | 11/9/2022 | View on chart |
| INGR | ▲ Buy | Grant | 713 | $58K | 10/3/2022 | View on chart |
| INGR | ▲ Buy | Grant | 669 | $59K | 7/1/2022 | View on chart |
| INGR | ▲ Buy | Grant | 694 | $59K | 4/1/2022 | View on chart |
| INGR | ▲ Buy | Grant | 619 | $60K | 1/3/2022 | View on chart |
| CAH | ▲ Buy | Grant | 6,215 | $0 | 11/11/2021 | View on chart |
| INGR | ▲ Buy | Grant | 573 | $52K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target
Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target. Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.